HeimAUROPHARMA • NSE
add
Aurobindo Pharma Ltd
Við síðustu lokun
1.103,40 ₹
Dagbil
1.104,00 ₹ - 1.137,50 ₹
Árabil
581,25 ₹ - 1.177,10 ₹
Markaðsvirði
662,87 ma. INR
Meðalmagn
1,48 m.
V/H-hlutf.
23,92
A/V-hlutfall
0,40%
Aðalkauphöll
NSE
Viðskiptafréttir
Fjármál
Rekstrarreikningur
Tekjur
Nettótekjur
| (INR) | des. 2023info | Breyting á/á |
|---|---|---|
Tekjur | 73,52 ma. | 14,74% |
Rekstrarkostnaður | 30,23 ma. | 5,46% |
Nettótekjur | 9,36 ma. | 90,59% |
Hagnaðarhlutfall | 12,74 | 66,10% |
Hagnaður á hvern hlut | 16,04 | 91,41% |
EBITDA | 14,59 ma. | 64,96% |
Virkt skatthlutfall | 25,54% | — |
Efnahagsreikningur
Heildareignir
Heildarskuldir
| (INR) | des. 2023info | Breyting á/á |
|---|---|---|
Reiðufé og skammtímafjárfestingar | 71,49 ma. | 10,47% |
Heildareignir | — | — |
Heildarskuldir | — | — |
Eigið fé alls | 281,95 ma. | — |
Útistandandi hlutabréf | 583,72 m. | — |
Eiginfjárgengi | 2,31 | — |
Arðsemi eigna | — | — |
Ávöxtun eigin fjár | 8,45% | — |
Peningaflæði
Breyting á handbæru fé
| (INR) | des. 2023info | Breyting á/á |
|---|---|---|
Nettótekjur | 9,36 ma. | 90,59% |
Handbært fé frá rekstri | — | — |
Reiðufé frá fjárfestingum | — | — |
Reiðufé frá fjármögnun | — | — |
Breyting á handbæru fé | — | — |
Frjálst peningaflæði | — | — |
Um
Aurobindo Pharma Limited is an Indian multinational pharmaceutical manufacturing company headquartered in HITEC City, Hyderabad, India. The company manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company’s area of activity includes six major therapeutic and product areas: antibiotics, anti-retrovirals, cardiovascular products, central nervous system products, gastroenterologicals, and anti-allergics. The company markets these products in over 125 countries. Its marketing partners include AstraZeneca and Pfizer. Wikipedia
Stofnsett
1986
Höfuðstöðvar
Vefsvæði
Starfsfólk
23.451
